Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for January 2012
January 3, 2012
- AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial
- Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
- Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes
- Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and Secondary Endpoints
January 4, 2012
- OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
- Alnylam Reports Positive Preliminary Clinical Results for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia
- Despite International Concern, U-M Study Shows 2006 Re-introduction of Rotavirus Vaccine Not Linked to Increase in Intussusception
January 5, 2012
- ProFibrix US Phase II Study with Fibrocaps Meets All Primary and Secondary Endpoints
- Tetragenetics' G-SOME-Formulated Influenza Vaccine Provides Strong Protection Against H5N1 in Preclinical Efficacy Study
- Major milestone achieved: the Phase IIa clinical trial in rheumatoid arthritis meets its endpoint
- Goff Hill Ltd. Announces the Cure for Cancer and Viral Diseases
- OrbusNeich's Genous Stent Achieves Good, Comparable Clinical Outcomes in Patients Discontinuing Dual Antiplatelet Therapy at 30 Days and at Six Months
- Tekmira?s LNP Technology Enables Alnylam?s Positive ALN-PCS Clinical Data
- RegeneRx Receives Clinical Study Report for Phase 2 Dry Eye Trial
- DURECT Announces Top-line Data from BESST (POSIDUR) U.S. Pivotal Phase III Trial
January 6, 2012
- Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson's Disease
- Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
January 9, 2012
- Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study
- Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
January 10, 2012
- Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova to Lovaza
- Dabigatran Associated with Increased Risk of Acute Coronary Events
- LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
- Techulon's Platform Demonstrates Effective Non-Viral DNA Delivery for in vivo Cardiac Study
- Civitas Therapeutics Announces Positive Results from Clinical Study of CVT-301, an Inhaled L-dopa for Parkinson?s Disease
- Achillion Reports Clinical Data on Portfolio of Protease Inhibitors
- Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayer's Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
January 11, 2012
- Vical Provides Updates on CMV Vaccine Programs
- Spherix Announces Successful Completion of Important Toxicology Study of SPX-106
- Potential Role of Natural Alkaloids in Combatting Memory Loss
- Cannabis Science Reports Apparent Success For 3rd Self-Medicated Cancer Patient
- Ember Therapeutics Announces Nature Publication of Brown Fat Biology Data; Program Exclusively Licensed from the Dana-Farber Cancer Institute
- Research in Rare Genetic Disease Poised to Provide New Therapies, According to New White Paper from Tuberous Sclerosis Alliance
January 12, 2012
- Synta Pharmaceuticals and University of Toronto Researchers Elucidate Elesclomol Mechanism of Action Using Innovative Yeast-based Technology
- Researchers Find First Major Gene Mutation Associated With Hereditary Prostate Cancer Risk
- Conventional Nerve Repair Wisdom Defied in First-Ever Multicenter Clinical Study with Processed, Donated Nerve Tissue
January 13, 2012
January 17, 2012
- REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function
- "O-Shot" May Improve Female Sexual Response
- Medivation and Pfizer Announce Results from Phase 3 Concert Trial of Dimebon in Alzheimer's Disease
- Colby Pharmaceutical Company Announces Publication of JVRS-100 use as Potent Immune Activating Adjuvant in Combination with H5N1 Influenza Vaccine
- ArQule Announces Tivantinib Meets Primary Endpoint, Significantly Extending Time to Progression in Phase 2 Trial in Second-Line Hepatocellular Carcinoma
- Synta Announces Publication of Results Showing Ganetespib Synergizes with Taxanes in Multiple Non-small Cell Lung Cancer Models
- First Preclinical Proof-of-Concept of Mutation-Based Individualized Cancer Vaccine
- Pevion's Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees
- BrainStorm Announces Clinical Data Supporting Safety and Efficacy of NurOwn Based on Initial Patient Results
- Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
- PV-10 Mechanism of Action Data to Be Presented at the Society of Surgical Oncology Annual Meeting March 21-24, 2012 in Orlando, Florida
- Scripps-led Study in JAMA Shows New Drug Helps "Bridge" Stent Patients to Cardiac Surgery
January 18, 2012
- Drug Helps Maintain Platelet Inhibition and Anti-Clotting Levels Prior To Cardiac Surgery
- PROLOR Biotech Announces Positive Top-Line Results From Pilot Study of Its Long-Acting Human Growth Hormone Injected Twice Per Month
- InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting Complement Driven Inflammation
- Soligenix Demonstrates Robust Stability Results with its SGX204 Anthrax Vaccine
- Prolor Biotech Announces Positive Top-Line Results From Pilot Study of Its Long-Acting Human Growth Hormone Injected Twice Per Month
January 19, 2012
- OncoGenex Announces Presentation of OGX-427 Data at the ASCO 2012 Genitourinary Cancers Symposium
- Researchers Uncover How New Melanoma Drug Accelerates Secondary Skin Cancers
- Combination of Oral Drugs Suppresses Common Type of Hepatitis C, According to University of Michigan-led Research
- Pregnant Women Who Develop Life-Threatening Blood Clots Should Receive Aggressive Treatment, Research At ISET 2012 Shows
- Cannabis Science Updates Second Medical Cannabis Cancer Patient Suffering from Squamous Cell Carcinoma Photo-documents Cannabis Extracts Killing Cancerous Tumor
- Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapies
- Drug Improves Survival of Colorectal Cancer Patients, Trial Results Show
January 20, 2012
- Infinity Reports New Data from Phase 1b Trial of Saridegib in Patients with Pancreatic Cancer at ASCO-GI
- Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma
January 23, 2012
- VentiRx Pharmaceuticals Publishes Preclinical Data of Novel TLR8 Agonist, VTX-2337, Supporting Its Potential as an Immunotherapeutic Approach in Cancer
- BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
- Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
January 24, 2012
- Cannabis Science Updates Latest Remarkable Follow up Photographs Received from 3rd Cancer Patient
- LifeSci Advisors Publishes JAKAFI Survey Results
- Recent Study Reveals Benefits to Women From DHEA Hormone
- LifeSci Advisors Publishes JAKAFI Survey Results
January 25, 2012
January 30, 2012
- Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial
- Compugen Presents Three Product Candidates for Treatment of Autoimmune Diseases at the Immunotherapeutics & Immunomonitoring Conference
- Infinity Reports Update from Phase 2 Study of Saridegib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer
- Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are Now Pain Free
- Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS in Front-line Mature T-Cell Lymphomas
- ImmunoCellular Therapeutics To Deliver Presentation on Cancer Stem Cells at Prestigious Immunotherapy Conference
- Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy Forum
- Synageva BioPharma Highlights Key Data Presentations at Upcoming Lysosomal Disease Network (LDN) World Symposium
- Results of NoNO Inc.-Sponsored Phase 2 Clinical Trial in Procedurally-Induced Strokes to be Announced at the International Stroke Conference
- VGX-100 Identified as Potential New Therapy for Improving Corneal Graft Survival
- Inherited Risk Factors for Childhood Leukemia are More Common in Hispanic Patients
January 31, 2012
- Exciting Data from Remedy Pharmaceutical-Sponsored Stroke Drug Trial to Be Presented at the 2012 International Stroke Conference in New Orleans
- BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure
- Vical Presents Case Study on Successful Design of Allovectin Phase 3 Melanoma Trial
- Inovio Pharmaceuticals Moves Closer to ?Universal? Influenza Vaccine By Demonstrating Protective Immune Responses against Multiple H3N2 and Type B Strains in Animal Studies
- HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial
- Inovio Pharmaceuticals Moves Closer to "Universal" Influenza Vaccine by Demonstrating Protective Immune Responses Against Multiple H3N2 and Type B Strains in Animal Studies
- Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement in Pain Relief for its Lead Product, Ampion(TM) in the Osteoarthritis of the Knee Trial.
- Argos Therapeutic Arcelis Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
